The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 25.83 — safe zoneOK
Where the revenue comes from
Fiscal 2025, as Kairos Pharma, LTD. reports it. History and quarterly detail are in the app.
- Item One And Two$100.0M
- Phase Three Clinical Trial$50.0M
- Item Four$50.0M
- Item One Two And Three$5.0M
Leadership changes
From Kairos Pharma, LTD.'s own filings, the day they're filed.
- Rahul Singhvi · director · appointmenteff. 2024-12-10
- Rosemary Mazanet · member of the board of directors · departure
Latest filings
- 8-K · Company announcement2026-08-21
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-06-30
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Kairos Pharma, LTD., every answer cited to the official filings🔒
- The Intelligence Brief — added when Kairos Pharma, LTD.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.